A BILL 
To authorize the collection of supplemental payments to in-
crease congressional investments in medical research, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Medical Innovation Act 
4
of 2019’’. 
5
01:55 Nov 20, 2019
H5031
2 
•HR 5031 IH
SEC. 2. AUTHORITY TO ASSESS AND USE SUPPLEMENTAL 
1
PAYMENTS TO INCREASE CONGRESSIONAL 
2
INVESTMENTS IN MEDICAL RESEARCH. 
3
(a) IN GENERAL.—Section 301 of the Public Health 
4
Service Act (42 U.S.C. 241) is amended by adding at the 
5
end the following: 
6
‘‘(i) AUTHORITY TO ASSESS
AND USE SUPPLE-
7
MENTAL PAYMENTS TO INCREASE CONGRESSIONAL IN-
8
VESTMENTS IN MEDICAL RESEARCH.— 
9
‘‘(1) DEFINITIONS.—For purposes of this sub-
10
section: 
11
‘‘(A) COVERED BLOCKBUSTER DRUG.— 
12
‘‘(i) IN GENERAL.—The term ‘covered 
13
blockbuster drug’ means any product— 
14
‘‘(I) for which the covered manu-
15
facturer reported to the Securities and 
16
Exchange Commission on a form, in-
17
cluding form 10–K or form 20–F, or 
18
is otherwise determined by the Sec-
19
retary to have received, at least 
20
$1,000,000,000 in net sales in the 
21
previous calendar year; and 
22
‘‘(II) that was developed, in 
23
whole or in part, through Federal 
24
Government investments in medical 
25
01:55 Nov 20, 2019
H5031
3 
•HR 5031 IH
research, as the Secretary determines 
1
in accordance with clause (ii). 
2
‘‘(ii) DETERMINATION
OF
FEDERAL 
3
GOVERNMENT
INVESTMENT.—In 
deter-
4
mining under clause (i)(II) whether a 
5
product was developed, in whole or in part, 
6
through Federal Government investments 
7
in medical research, the Secretary shall 
8
consider whether information included in 
9
any patent that claims the covered block-
10
buster drug or that claims a method of 
11
using such covered blockbuster drug and 
12
with respect to which a claim of patent in-
13
fringement could reasonably be asserted if 
14
a person not licensed by the owner engaged 
15
in the manufacture, use, or sale of the cov-
16
ered blockbuster drug, or any element of 
17
the covered blockbuster drug— 
18
‘‘(I) relates to, or is based upon, 
19
prior science conducted, in whole or in 
20
part, by a person that is or was fund-
21
ed by the Federal Government; 
22
‘‘(II) relates to, acts upon, or is 
23
based upon knowledge of a signaling 
24
pathway, cellular receptor, ion chan-
25
01:55 Nov 20, 2019
H5031
4 
•HR 5031 IH
nel, protein, DNA or RNA sequence 
1
or mutation, virus, or any other sci-
2
entific 
information 
discovered, 
in 
3
whole or in part, through research 
4
funded by the Federal Government; or 
5
‘‘(III) relates to, or is based 
6
upon, through the manufacturing 
7
process or testing process of the cov-
8
ered blockbuster drug, technology de-
9
rived, in whole or in part, through re-
10
search funded by the Federal Govern-
11
ment. 
12
‘‘(B) 
COVERED
MANUFACTURER.—The 
13
term ‘covered manufacturer’ means a person— 
14
‘‘(i) that holds an application ap-
15
proved under section 505 of the Federal 
16
Food, Drug, and Cosmetic Act or a license 
17
under section 351 of this Act for a covered 
18
blockbuster drug; or 
19
‘‘(ii) who is a co-licensed partner of 
20
the person described in clause (i) that ob-
21
tains the covered blockbuster drug directly 
22
from a person described in this clause or 
23
clause (i). 
24
01:55 Nov 20, 2019
H5031
5 
•HR 5031 IH
‘‘(C) 
COVERED
SETTLEMENT
AGREE-
1
MENT.— 
2
‘‘(i) IN GENERAL.—The term ‘covered 
3
settlement agreement’ means a settlement 
4
agreement (including a consent decree), 
5
and except as provided under clause (ii)— 
6
‘‘(I) that is between an agency 
7
and a covered manufacturer; 
8
‘‘(II) that relates to— 
9
‘‘(aa) an alleged violation of, 
10
or 
a 
penalty 
under, 
section 
11
1128A of the Social Security Act 
12
or section 1128B of the Social 
13
Security Act; 
14
‘‘(bb) an alleged violation 
15
under subchapter III of chapter 
16
37 of title 31, United States 
17
Code (commonly known as the 
18
‘False Claims Act’); 
19
‘‘(cc) an alleged violation 
20
under the Federal Food, Drug, 
21
and Cosmetic Act; or 
22
‘‘(dd) an alleged violation of 
23
any other Federal civil or crimi-
24
nal law; and 
25
01:55 Nov 20, 2019
H5031
6 
•HR 5031 IH
‘‘(III) under the terms of which a 
1
covered manufacturer is obligated in 
2
an amount not less than a total of 
3
$1,000,000, including civil or criminal 
4
penalties with respect to any parties, 
5
including governmental and private 
6
entities. 
7
‘‘(ii) EXCEPTION FOR SETTLEMENTS 
8
NOT
AFFECTING
TAXPAYERS
OR
PUBLIC 
9
HEALTH.—The term ‘covered settlement 
10
agreement’ does not include any settlement 
11
agreement that the Secretary determines— 
12
‘‘(I) does not involve an alleged 
13
criminal violation; and 
14
‘‘(II) does not to relate to— 
15
‘‘(aa) allegations of fraud re-
16
sulting, or potentially resulting, 
17
in a loss of taxpayer dollars; or 
18
‘‘(bb) allegations of conduct 
19
having an adverse impact, or a 
20
potentially adverse impact, on the 
21
health of the public. 
22
‘‘(D) PERSON.—The term ‘person’ has the 
23
meaning given such term in section 201(e) of 
24
the Federal Food, Drug, and Cosmetic Act. 
25
01:55 Nov 20, 2019
H5031
7 
•HR 5031 IH
‘‘(E) 
PRODUCT.—The 
term 
‘product’ 
1
means a drug approved under section 505 of 
2
the Federal Food, Drug, and Cosmetic Act or 
3
licensed under section 351, and subject to sec-
4
tion 503(b)(1) of the Federal Food, Drug, and 
5
Cosmetic Act. 
6
‘‘(2) SUPPLEMENTAL PAYMENTS TO INCREASE 
7
CONGRESSIONAL
INVESTMENTS
IN
MEDICAL
RE-
8
SEARCH.— 
9
‘‘(A) SUPPLEMENTAL
PAYMENT
ASSESS-
10
MENT AND COLLECTION.—Beginning with the 
11
first fiscal year that begins at least 60 days 
12
after the date of enactment of the Medical In-
13
novation Act of 2019, and each subsequent fis-
14
cal year, the Secretary shall, in accordance with 
15
this paragraph, assess and collect supplemental 
16
payments to increase congressional investments 
17
in medical research from each covered manufac-
18
turer described in subparagraph (B). 
19
‘‘(B) CRITERIA
FOR
ASSESSING
PAY-
20
MENTS.—A covered manufacturer that meets 
21
both of the following criteria for a calendar year 
22
(referred to in this subparagraph and subpara-
23
graph (D) as the ‘applicable calendar year’) 
24
shall be assessed a supplemental payment under 
25
01:55 Nov 20, 2019
H5031
8 
•HR 5031 IH
subparagraph (A) for the fiscal year beginning 
1
in the proceeding calendar year: 
2
‘‘(i) A covered manufacturer that, 
3
during the 5-year period immediately pre-
4
ceding the date on which the payment is 
5
assessed, but not before the date of enact-
6
ment of the Medical Innovation Act of 
7
2019, entered into a covered settlement 
8
agreement. 
9
‘‘(ii) A covered manufacturer that re-
10
ported 
net 
income 
of 
at 
least 
11
$1,000,000,000 to the Securities and Ex-
12
change Commission on a form, including 
13
form 10–K or form 20–F, or that the Sec-
14
retary otherwise determines to have had 
15
net income of at least $1,000,000,000— 
16
‘‘(I) during the applicable cal-
17
endar year; or 
18
‘‘(II) during the calendar year in 
19
which the covered manufacturer en-
20
tered into a covered settlement agree-
21
ment, as described in clause (i). 
22
‘‘(C) PAYMENT AMOUNT.— 
23
‘‘(i) IN GENERAL.—A covered manu-
24
facturer described in subparagraph (B) 
25
01:55 Nov 20, 2019
H5031
9 
•HR 5031 IH
shall be assessed a supplemental payment 
1
to increase congressional investments in 
2
medical research for a fiscal year equal to 
3
the applicable percentage of the net income 
4
of the covered manufacturer, as reported 
5
or determined as described in subpara-
6
graph (B)(ii), for the previous calendar 
7
year, multiplied by the number of covered 
8
blockbuster drugs of the covered manufac-
9
turer for that year. 
10
‘‘(ii) APPLICABLE PERCENTAGE.—For 
11
purposes of determining the amount of a 
12
supplemental payment under clause (i), the 
13
applicable percentage of the net income of 
14
a covered manufacturer is— 
15
‘‘(I) 0.75 percent, in the case of 
16
a covered settlement agreement under 
17
the terms of which the total obligation 
18
of a covered manufacturer is in an 
19
amount 
that 
is 
less 
than 
20
$500,000,000; 
21
‘‘(II) 1 percent, in the case of a 
22
covered settlement agreement under 
23
the terms of which the total obligation 
24
of a covered manufacturer is in an 
25
01:55 Nov 20, 2019
H5031
10 
•HR 5031 IH
amount that is at least $500,000,000 
1
but less than $1,000,000,000; or 
2
‘‘(III) 1.5 percent, in the case of 
3
a covered settlement agreement under 
4
the terms of which the total obligation 
5
of a covered manufacturer is in an 
6
amount 
that 
is 
at 
least 
7
$1,000,000,000. 
8
‘‘(D) ANNUAL LIMITATION.—In the case of 
9
a covered manufacturer that entered into more 
10
than 1 covered settlement agreement during an 
11
applicable calendar year, such covered manufac-
12
turer shall be assessed a supplemental payment 
13
under subparagraph (C) only with respect to 
14
the covered settlement agreement under which 
15
the total amount obligated of the covered manu-
16
facturer, 
as 
described 
in 
paragraph 
17
(1)(C)(i)(III), is the highest. 
18
‘‘(E) PUBLICATION
OF
PAYMENTS.—Be-
19
ginning with the first fiscal year that begins at 
20
least 60 days after the date of enactment of the 
21
Medical Innovation Act of 2019, and not later 
22
than 60 days before the start of each fiscal 
23
year, the Secretary shall publish in the Federal 
24
Register, with respect to the next fiscal year— 
25
01:55 Nov 20, 2019
H5031
11 
•HR 5031 IH
‘‘(i) a list of covered manufacturers 
1
subject to the payment under this para-
2
graph; 
3
‘‘(ii) a list of the covered blockbuster 
4
drugs of each such covered manufacturer; 
5
‘‘(iii) the total payment amount as-
6
sessed to each such covered manufacturer; 
7
and 
8
‘‘(iv) the manner in which payments 
9
assessed under this paragraph will be col-
10
lected. 
11
‘‘(F) CREDITING
AND
AVAILABILITY
OF 
12
SUPPLEMENTAL PAYMENTS.— 
13
‘‘(i) IN GENERAL.—Subject to clause 
14
(ii), payments authorized under this para-
15
graph shall be collected and available for 
16
obligation only to the extent and in the 
17
amount provided in advance in appropria-
18
tions Acts. Such payments are authorized 
19
to remain available until expended. 
20
‘‘(ii) COLLECTIONS
AND
APPROPRIA-
21
TIONS ACTS.— 
22
‘‘(I) IN
GENERAL.—The pay-
23
ments authorized by this paragraph— 
24
01:55 Nov 20, 2019
H5031
12 
•HR 5031 IH
‘‘(aa) subject to subclause 
1
(II), shall be collected and avail-
2
able in each fiscal year in an 
3
amount not to exceed the amount 
4
specified in appropriation Acts, 
5
or otherwise made available for 
6
obligation, for such fiscal year; 
7
and 
8
‘‘(bb) shall be available to 
9
the Secretary to distribute, as de-
10
scribed in paragraph (3). 
11
‘‘(II) PROVISION
FOR
EARLY 
12
PAYMENTS.—Payments 
authorized 
13
under clause (iii) for a fiscal year, 
14
prior to the due date for such pay-
15
ments, may be accepted by the Sec-
16
retary. 
17
‘‘(iii) AUTHORIZATION OF APPROPRIA-
18
TIONS.—For the first fiscal year that be-
19
gins at least 60 days after the date of en-
20
actment of the Medical Innovation Act of 
21
2019 and for each subsequent fiscal year, 
22
there is authorized to be appropriated for 
23
the purpose of making distributions under 
24
paragraph (3) to meet the priorities de-
25
01:55 Nov 20, 2019
H5031
13 
•HR 5031 IH
scribed in paragraph (4), an amount equal 
1
to the total amount of supplemental pay-
2
ments assessed for such fiscal year under 
3
this paragraph. 
4
‘‘(G) REMITTING
PAYMENTS.—A covered 
5
manufacturer assessed a supplemental payment 
6
under subparagraph (A) shall remit the pay-
7
ment no later than the first business day on or 
8
after October 1 of each fiscal year, or the first 
9
business day after the date of enactment of an 
10
appropriations Act providing for the collection 
11
and obligation of supplemental payments for 
12
such fiscal year. 
13
‘‘(H) COLLECTION
OF
ASSESSED
PAY-
14
MENTS THAT ARE NOT REMITTED.—In any case 
15
where the Secretary does not receive a supple-
16
mental payment assessed under subparagraph 
17
(A) within 30 days after it is due, such supple-
18
mental payment shall be treated as a claim of 
19
the United States Government subject to sub-
20
chapter II of chapter 37 of title 31, United 
21
States Code. 
22
‘‘(I) SUPPLEMENT NOT SUPPLANT.—Pay-
23
ments collected under this paragraph shall be 
24
used to supplement and not supplant other 
25
01:55 Nov 20, 2019
H5031
14 
•HR 5031 IH
Federal funds made available to carry out the 
1
priorities described in paragraph (4). 
2
‘‘(3) DISTRIBUTION OF PAYMENTS TO AGEN-
3
CIES TO INCREASE CONGRESSIONAL INVESTMENTS 
4
IN MEDICAL RESEARCH.— 
5
‘‘(A) DISTRIBUTION TO AGENCIES.—Sub-
6
ject to subparagraph (C), for the purposes de-
7
scribed in paragraph (4), the Secretary shall 
8
distribute the amounts appropriated under 
9
paragraph (2)(F)(iii) during a fiscal year to— 
10
‘‘(i) the Food and Drug Administra-
11
tion, to be used in accordance with para-
12
graph (4)(A); and 
13
‘‘(ii) the National Institutes of Health 
14
organized under title IV, to be used in ac-
15
cordance with paragraph (4)(B). 
16
‘‘(B) 
DISTRIBUTION
RATIO
BETWEEN 
17
AGENCIES.—The amount that the Secretary 
18
distributes to an agency under subparagraph 
19
(A) during a fiscal year shall bear the same re-
20
lation to the total amount appropriated under 
21
paragraph (2)(F)(iii) for such fiscal year as the 
22
amount of discretionary funds appropriated to 
23
such agency for such fiscal year bears to the 
24
total amount of discretionary funding appro-
25
01:55 Nov 20, 2019
H5031
15 
•HR 5031 IH
priated to both agencies listed in subparagraph 
1
(A) for such fiscal year. 
2
‘‘(C) ENSURING STABLE CONGRESSIONAL 
3
INVESTMENTS IN MEDICAL RESEARCH.— 
4
‘‘(i) IN GENERAL.—Supplemental pay-
5
ments collected in accordance with para-
6
graph (2) shall not be distributed under 
7
subparagraph (A) for a fiscal year unless 
8
appropriations to both of the agencies list-
9
ed in such subparagraph for the fiscal year 
10
are equal to or greater than appropriations 
11
to such agencies for the prior fiscal year. 
12
‘‘(ii) DELAYED DISTRIBUTION.—If, in 
13
accordance with clause (i), the Secretary 
14
does not distribute payments collected in 
15
accordance with paragraph (2) during any 
16
portion of a fiscal year, and, at a later 
17
date in such fiscal year, the appropriations 
18
to the agencies listed in subparagraph (A) 
19
become equal to or greater than the 
20
amount of appropriations for the prior fis-
21
cal year, the Secretary may distribute such 
22
payment at any time in such fiscal year. 
23
01:55 Nov 20, 2019
H5031
16 
•HR 5031 IH
‘‘(D) CONSIDERATIONS.—In determining 
1
amounts appropriated for purposes of subpara-
2
graphs (B) and (C)— 
3
‘‘(i) the Secretary shall not consider 
4
any amounts appropriated in accordance 
5
with paragraph (2)(F)(iii); and 
6
‘‘(ii) with respect to the Food and 
7
Drug Administration, the Secretary shall 
8
not consider amounts appropriated in ac-
9
cordance with subchapter C of chapter VII 
10
of the Federal Food, Drug, and Cosmetic 
11
Act (relating to user fees collected by the 
12
Secretary). 
13
‘‘(4) PRIORITIZING URGENT NEEDS IN MEDICAL 
14
RESEARCH.—The Secretary shall ensure that the 
15
payments distributed under paragraph (3) are used 
16
to meet urgent needs in medical research, including 
17
priorities as follows: 
18
‘‘(A) FDA.—With respect the Food and 
19
Drug Administration, the priority use of the 
20
distributions shall include carrying out the 
21
goals of the strategy and implementation plan 
22
for advancing regulatory science for medical 
23
products under section 1124 of the Food and 
24
Drug Administration Safety and Innovation Act 
25
01:55 Nov 20, 2019
H5031
17 
•HR 5031 IH
(21 U.S.C. 393 note), and other such research 
1
activities in order to promote the public health 
2
and advance innovation in regulatory decision-
3
making, as determined by the Secretary. 
4
‘‘(B) NIH.—With respect to the National 
5
Institutes of Health, the priority use of the dis-
6
tributions shall include supporting— 
7
‘‘(i) research that fosters radical inno-
8
vation, including— 
9
‘‘(I) research on diseases or con-
10
ditions for which treatments exist but 
11
are inadequate; 
12
‘‘(II) research on diseases or con-
13
ditions for which there are unmet 
14
medical needs; 
15
‘‘(III) research on diseases for 
16
which treatments exist but the side ef-
17
fect profiles of such treatments limit 
18
the therapeutic potential of such 
19
treatments; 
20
‘‘(IV) 
research 
on 
new 
ap-
21
proaches to treatment or diagnosis of 
22
a disease using a drug, device, or 
23
therapy that, at the time of distribu-
24
tion, is not used or is underused; or 
25
01:55 Nov 20, 2019
H5031
18 
•HR 5031 IH
‘‘(V) research to identify new bio-
1
markers; 
2
‘‘(ii) research that advances funda-
3
mental knowledge and technology even if it 
4
does not provide immediate or near-term 
5
clinical or therapeutic benefits, including 
6
research and technology that advances the 
7
understanding of biochemistry, biology, 
8
protein science, immunology, genetics, vi-
9
rology, microbiology, or neurology; 
10
‘‘(iii) research related to diseases that 
11
disproportionally 
account 
for 
Federal 
12
health care spending, including spending 
13
under the Medicare program under title 
14
XVIII of the Social Security Act, the Med-
15
icaid program under title XIX of the Social 
16
Security Act, the State Children’s Health 
17
Insurance Program under title XXI of the 
18
Social Security Act, the TRICARE pro-
19
gram under chapter 55 of title 10, United 
20
States Code, and the hospital services and 
21
medical care provided through the Vet-
22
erans’ Administration under chapters 17 
23
and 18 of title 38, United States Code, 
24
and tax credits made available through the 
25
01:55 Nov 20, 2019
H5031
19 
•HR 5031 IH
amendments to the Internal Revenue Code 
1
of 1986 made by the Patient Protection 
2
and Affordable Care Act (Public Law 111– 
3
148), such as research relating to— 
4
‘‘(I) diseases that disproportion-
5
ally impact older individuals; 
6
‘‘(II) degenerative diseases, and 
7
‘‘(III) chronic conditions; and 
8
‘‘(iv) early career scientists by— 
9
‘‘(I) awarding research project 
10
grants that support discrete, specified, 
11
circumscribed projects to be per-
12
formed by the investigator in an area 
13
representing the specific interests and 
14
competencies of such investigator, to 
15
investigators— 
16
‘‘(aa) who are within 10 
17
years of completing a terminal 
18
research degree; or 
19
‘‘(bb) who are within 10 
20
years of completing a medical 
21
residency; 
22
‘‘(II) awarding grants that sup-
23
port career development experiences 
24
01:55 Nov 20, 2019
H5031
20 
•HR 5031 IH
that lead to earlier research independ-
1
ence; and 
2
‘‘(III) awarding grants that sup-
3
port innovative training programs 
4
that, in addition to scientific training, 
5
provide additional training to enhance 
6
employment opportunities, including 
7
training in management and business, 
8
to— 
9
‘‘(aa) graduate students; 
10
‘‘(bb) post-doctoral fellows; 
11
‘‘(cc) individuals within 10 
12
years of completing a terminal 
13
research degree; or 
14
‘‘(dd) individuals within 10 
15
years of completing a medical 
16
residency. 
17
‘‘(5) ANNUAL REPORTS.— 
18
‘‘(A) SECRETARY OF HEALTH AND HUMAN 
19
SERVICES.—Not later than 180 calendar days 
20
before the end of a fiscal year in which the Sec-
21
retary has assessed supplemental payments 
22
under paragraph (2), the Secretary shall submit 
23
a report to the Committee on Health, Edu-
24
cation, Labor, and Pensions of the Senate and 
25
01:55 Nov 20, 2019
H5031
21 
•HR 5031 IH
the Committee on Energy and Commerce of the 
1
House of Representatives, which shall include a 
2
description of supplemental payments assessed, 
3
collected, and distributed under this subsection 
4
for such fiscal year, and a list of the covered 
5
manufacturers that were assessed supplemental 
6
payments and the amount of such assessments. 
7
‘‘(B) FDA AND NIH.—For each fiscal year 
8
in which amounts are distributed under para-
9
graph (3), the Food and Drug Administration 
10
and the National Institutes of Health shall re-
11
port on the use and impact of such amounts in 
12
the annual budget submission of such entity.’’. 
13
(b) EFFECT OF FAILURE TO REMIT PAYMENT.— 
14
Section 502 of the Federal Food, Drug, and Cosmetic Act 
15
(21 U.S.C. 352) is amended by adding at the end the fol-
16
lowing: 
17
‘‘(ee) If it is a drug that is a covered blockbuster drug 
18
(as defined in section 301(i)(1) of the Public Health Serv-
19
ice Act) for which any payment assessed under section 
20
301(i)(2) of such Act has not been paid in accordance with 
21
such section, until such payment is made.’’. 
22
(c) SEVERABILITY.—If any provision of this section, 
23
any amendment made by this section, or the application 
24
of such provision or amendment to any person or cir-
25
01:55 Nov 20, 2019
H5031
22 
•HR 5031 IH
cumstance is held to be unconstitutional, the remainder 
1
of the provisions of this section, the amendments made 
2
by this section, and the application of such provisions or 
3
amendments to any person or circumstance shall not be 
4
affected. 
5
Æ 
01:55 Nov 20, 2019
H5031
